在老年精神障碍患者中使用氯氮平的经验。

IF 3.8 4区 医学 Q1 PSYCHIATRY
Sandeep Grover, Pranshu Sharma, Subho Chakrabarti
{"title":"在老年精神障碍患者中使用氯氮平的经验。","authors":"Sandeep Grover,&nbsp;Pranshu Sharma,&nbsp;Subho Chakrabarti","doi":"10.1016/j.ajp.2024.104143","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>There is little information on using clozapine in elderly patients with mental disorders from India.</p></div><div><h3>Aim</h3><p>To evaluate the sociodemographic and clinical profile of elderly (age ≥ 60 years) patients started on clozapine.</p></div><div><h3>Methodology</h3><p>The clozapine registry in the department was screened to identify elderly patients who were started on clozapine. Treatment records of these patients were reviewed to extract sociodemographic and clinical details.</p></div><div><h3>Results</h3><p>Out of the available information of 1058 patients in the registry, 42 (3.96 %) were elderly (≥ 60 years) patients. About two-thirds of the patients had treatment resistance, i.e., their psychotic illness had not responded to two adequate trials of antipsychotics, and the second most common indication for starting clozapine was tardive dystonia or tardive dyskinesia (23.8 %). The mean dose of clozapine was 135.89 (SD: 109.6; Range: 37.5–500; median: 87.5) mg/day. The mean duration of clozapine use at the time of data extraction for the study sample was 3.55 (SD: 2.15; Range 0.3–9; median: 3) years. At the last follow-up, about three-fourths of patients were experiencing at least one side effect, with constipation being the most common side effect, followed by sedation, weight gain, and hypersalivation. In only four patients, clozapine was stopped during the follow-up. In terms of effectiveness, majority of the patients were rated as much improved or very much improved on Clinical Global Impression-Improvement subscale.</p></div><div><h3>Conclusion</h3><p>Clozapine can be safely used in elderly patients with mental disorders. Hence, clozapine should not be withheld in elderly patients with mental disorders whenever indicated.</p></div>","PeriodicalId":8543,"journal":{"name":"Asian journal of psychiatry","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An experience of using Clozapine in elderly patients with mental disorders\",\"authors\":\"Sandeep Grover,&nbsp;Pranshu Sharma,&nbsp;Subho Chakrabarti\",\"doi\":\"10.1016/j.ajp.2024.104143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>There is little information on using clozapine in elderly patients with mental disorders from India.</p></div><div><h3>Aim</h3><p>To evaluate the sociodemographic and clinical profile of elderly (age ≥ 60 years) patients started on clozapine.</p></div><div><h3>Methodology</h3><p>The clozapine registry in the department was screened to identify elderly patients who were started on clozapine. Treatment records of these patients were reviewed to extract sociodemographic and clinical details.</p></div><div><h3>Results</h3><p>Out of the available information of 1058 patients in the registry, 42 (3.96 %) were elderly (≥ 60 years) patients. About two-thirds of the patients had treatment resistance, i.e., their psychotic illness had not responded to two adequate trials of antipsychotics, and the second most common indication for starting clozapine was tardive dystonia or tardive dyskinesia (23.8 %). The mean dose of clozapine was 135.89 (SD: 109.6; Range: 37.5–500; median: 87.5) mg/day. The mean duration of clozapine use at the time of data extraction for the study sample was 3.55 (SD: 2.15; Range 0.3–9; median: 3) years. At the last follow-up, about three-fourths of patients were experiencing at least one side effect, with constipation being the most common side effect, followed by sedation, weight gain, and hypersalivation. In only four patients, clozapine was stopped during the follow-up. In terms of effectiveness, majority of the patients were rated as much improved or very much improved on Clinical Global Impression-Improvement subscale.</p></div><div><h3>Conclusion</h3><p>Clozapine can be safely used in elderly patients with mental disorders. Hence, clozapine should not be withheld in elderly patients with mental disorders whenever indicated.</p></div>\",\"PeriodicalId\":8543,\"journal\":{\"name\":\"Asian journal of psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian journal of psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1876201824002363\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian journal of psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876201824002363","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于印度老年精神障碍患者使用氯氮平的信息很少:目的:评估开始使用氯氮平的老年患者(年龄≥ 60 岁)的社会人口学和临床概况:方法:对该部门的氯氮平登记册进行筛选,以确定开始使用氯氮平的老年患者。对这些患者的治疗记录进行审查,以提取社会人口学和临床细节:在登记的 1058 名患者中,有 42 名(3.96%)是老年患者(≥ 60 岁)。约三分之二的患者存在治疗耐药性,即他们的精神病对两种抗精神病药物的充分试验均无反应,开始使用氯氮平的第二大常见适应症是迟发性肌张力障碍或迟发性运动障碍(23.8%)。氯氮平的平均剂量为 135.89(标度:109.6;范围:37.5-500;中位数:87.5)毫克/天。在提取数据时,研究样本使用氯氮平的平均时间为 3.55 年(标度:2.15;范围:0.3-9;中位数:3)。在最后一次随访中,约四分之三的患者出现了至少一种副作用,其中便秘是最常见的副作用,其次是镇静、体重增加和唾液分泌过多。只有四名患者在随访期间停用了氯氮平。在疗效方面,大多数患者在临床总体印象-改善分量表中被评为 "大有改善 "或 "非常大的改善":结论:氯氮平可以安全地用于老年精神障碍患者。结论:氯氮平可以安全地用于老年精神障碍患者,因此,只要有必要,老年精神障碍患者不应禁用氯氮平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An experience of using Clozapine in elderly patients with mental disorders

Background

There is little information on using clozapine in elderly patients with mental disorders from India.

Aim

To evaluate the sociodemographic and clinical profile of elderly (age ≥ 60 years) patients started on clozapine.

Methodology

The clozapine registry in the department was screened to identify elderly patients who were started on clozapine. Treatment records of these patients were reviewed to extract sociodemographic and clinical details.

Results

Out of the available information of 1058 patients in the registry, 42 (3.96 %) were elderly (≥ 60 years) patients. About two-thirds of the patients had treatment resistance, i.e., their psychotic illness had not responded to two adequate trials of antipsychotics, and the second most common indication for starting clozapine was tardive dystonia or tardive dyskinesia (23.8 %). The mean dose of clozapine was 135.89 (SD: 109.6; Range: 37.5–500; median: 87.5) mg/day. The mean duration of clozapine use at the time of data extraction for the study sample was 3.55 (SD: 2.15; Range 0.3–9; median: 3) years. At the last follow-up, about three-fourths of patients were experiencing at least one side effect, with constipation being the most common side effect, followed by sedation, weight gain, and hypersalivation. In only four patients, clozapine was stopped during the follow-up. In terms of effectiveness, majority of the patients were rated as much improved or very much improved on Clinical Global Impression-Improvement subscale.

Conclusion

Clozapine can be safely used in elderly patients with mental disorders. Hence, clozapine should not be withheld in elderly patients with mental disorders whenever indicated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Asian journal of psychiatry
Asian journal of psychiatry Medicine-Psychiatry and Mental Health
CiteScore
12.70
自引率
5.30%
发文量
297
审稿时长
35 days
期刊介绍: The Asian Journal of Psychiatry serves as a comprehensive resource for psychiatrists, mental health clinicians, neurologists, physicians, mental health students, and policymakers. Its goal is to facilitate the exchange of research findings and clinical practices between Asia and the global community. The journal focuses on psychiatric research relevant to Asia, covering preclinical, clinical, service system, and policy development topics. It also highlights the socio-cultural diversity of the region in relation to mental health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信